Introduction approximately a 1.5-fold enhanced relative risk of Left ventricular hypertrophy (LVH), which occurs in cardiovascular disease and by a doubled risk of carapproximately 15-20% of adult hypertensive diovascular mortality. 5 patients, 1 is not simply an incidental compensatory Regression of hypertension-associated LVH can be phenomenon in response to the increased overload, achieved by the long-term administration of antihybut is recognized as a potent independent risk factor pertensive agents [6] [7] [8] and there is preliminary evifor cardiovascular morbidity and mortality. [1] [2] [3] [4] [5] The dence that the reversal of LVH might reduce the risk main cardiovascular events related to LVH in hyperof cardiovascular events. 9, 10 Clinical and experitensive patients are coronary heart disease, cardiac mental studies suggest that antihypertensive drugs failure, stroke and sudden death. In the Framingham may differ in their potencies to reduce LVH; in this Study, electrocardiographically detected LVH was sense, angiotensin-converting enzyme (ACE) inhibifound to be associated with a relative risk of cardiotors seem to be the most powerful drug class, folvascular disease as high as for hypercholesterolelowed by calcium antagonists, ␤-blockers and mia, cigarette smoking and diabetes together. 2 Howdiuretics, while vasodilators exhibit less or no effiever, anatomical LVH is more sensitively detected cacy. [6] [7] [8] 11, 12 Moreover, experimental studies showed by echocardiography than by electrocardiography or that, in spite of its excellent blood pressure (BP)-X-ray examination. 3 Recent echocardiographic studlowering potency, minoxidil, a direct vasodilator ies confirmed that the left ventricular mass (LVM) acting via activation of the ATP-sensitive potassium predicts a progressively increasing risk of mortal channels, can even induce or aggravate LVH, preand morbid cardiac events; 4, 5 each 50 g/m 2 increase sumably due to reflexive activation of the sympathetic and renin-angiotensin systems and the volume overload. [12] [13] [14] [15] In clinical studies, minoxidil in com- tension. 16, 17 There is only scanty experience on the January 1997 effect of minoxidil on LVM in human hypertensives; some early studies 18, 19 and one involving an echoRoche, Basel, Switzerland; n = 10), depending on the BP response, besides the bopindolol and guanfacine cardiographic assessment of LVM 20 demonstrated an aggravating effect of minoxidil on LVH, whereas they were already taking. All minoxidil-treated patients were given a diuretic (clopamide, 10 mg another echocardiographic investigation did not. 21 The primary aim of the present study, therefore, daily) to counteract fluid retention. When necessary, the dose of clopamide was increased throughout the was to investigate the effect of the long-term administration of minoxidil on echocardiographically study. A third group of patients (n = 6) received both minoxidil (15-30 mg/day) and cilazapril (3-5 detected LVH in patients with severe hypertension in comparison with that of cilazapril, a new, longmg/day) in addition to the bopindolol+guanfacine therapy. The application of clopamide in this group acting ACE inhibitor, 22 the two drugs also being applied as combination therapy.
was ceased if possible. During the first month of treatment, the doses of cilazapril and minoxidil were titrated to achieve the target DBP of less than
Subjects and methods
100 mm Hg. Thereafter, BP, heart rate and clinical status were controlled every month. EchocardiograSubjects phy, electrocardiography and routine blood chemisAll patients (n = 26) selected for the study had sevtry analyses were performed before randomization ere essential hypertension and LVH. Their diastolic and every 3 months during the treament for 12 BP (DBP) levels amounted to 115 mm Hg on three months. separate occasions when they were not on antihypertensive therapy (baseline BP; Table 1 to help dose optimization. The protocol was planned in a randomized, prospective, open-labelled fashion because of the Echocardiography potentially adverse cardiac effects of minoxidil. As a run-in period, all patients were treated for 4 weeks M-mode echocardiography was performed by using an Ultramark 9 HDI echocardiograph (ATL, USA) with the ␤-receptor blocker bopindolol (1-2 mg/day) and with the centrally acting agent guanfacine (1-2 with a 3-2 MHz transducer. All echocardiograms were taken by the same investigator. Recordings mg/day). This run-in period was intended to make the pre-trial antihypertensive therapy comparable, were made at a paper speed of 50 mm/second. All echocardiograms were videorecorded. The internal since those patients with severe hypertension could not be deprived of drug treatment, 25 for ethical dimension of the left ventricle (LVIDd), IVST and PWT at end-diastole were measured according to the reasons.
After the 4-week period, patients were randomly recommendations of the American Society of Echocardiography. 26 All recordings were read by two allocated to treatment with either a dose of 15-40 mg/day minoxidil (Loniten®, Upjohn, Crawley, UK; independent observers who were blind to the patient's treatment status. All measurements were n = 10) or up to 5 mg/day cilazapril (Inhibace®, carried out over at least three cardiac cycles and throughout the study (Table 2 , Figure 1 ). There were no significant differences in BP responses between were averaged. LVM was estimated by the formula of Devereux and Reicheck: 27 the treatment groups. The average daily doses of the drugs required to maintain the antihypertensive
3 )−14g effect are listed in Table 3 . and was divided by the body surface area to derive
The minoxidil-based treatment resulted in a con-LVMI. Since the mean variability in the LVM tinuous significant decrease in TPR and a tendency measurement was approximately 25 g, changes of to increase in cardiac index (Table 2) ; at 3 months, у50 g were regarded as a statistically significant this latter reached a statistically significant differregression or aggravation of LVH in an individual ence (+15%, P Ͻ 0.05). On the other hand, the cilazpatient. 28 Relative wall thickness (RWT) was calcuapril-based regimen led to a significant decrease in lated as:
cardiac output throughout the treatment, while a significant fall in TPR was observed only transiently RWT = 2PWT/LVIDd.
(at 3 months; −9%, P Ͻ 0.05). In the minoxidil+ Left ventricular geometry was regarded as concencilazapril-treated group, both the cardiac index and tric hypertrophy (RWT Ͼ 0. 45 ). 4 Left ventricu-LVM and morphology lar end-diastolic and end-systolic volumes, determined by the formula of Teichholz et al, 29 were used Two-way repeated measures ANOVA revealed that to estimate stroke volume and cardiac output. Total the effects of different types of therapy on LVMI peripheral resistance (TPR) was calculated from depended on the duration of treatment (P Ͻ 0.001 MAP and the cardiac output index.
for the interaction between the kind and the length of therapy). Table 2 lists the echocardiographic variables of the three groups before and after treatment.
Clinical status
The minoxidil-based therapy led to a continuous Every month the patients were interviewed and increase in LVMI (+14.9% at 12 months, P Ͻ 0.05; examined for cardiovascular complaints, such as 1% at 12 months, P Ͻ 0.05) which was test for paired data, analysis of variance (ANOVA) mainly due to a decreasing tendency in LVIDd. In for repeated measures, Friedman's repeated measthe minoxidil+cilazapril-treated group, the calcuures ANOVA on ranks or the Kruskal-Wallis test lated LVMI showed a 6.0% decrease, which failed was used, as indicated. Relationships between varito reach statistical significance. ables were assessed by the Spearman rank correTaking a у50 g variation in LVM as an indicator lation procedure or by stepwise regression analysis, of a statistically significant regression or aggravation as appropriate. Categorical variables were evaluated of LVH, the individual data indicated that minoxiby the 2 -test, the McNemar test or the Fisher exact dil-based therapy led to an aggravation of LVH in test, as indicated. Statistical significance was six patients and failed to cause regression in any. defined as P Ͻ 0.05.
The cilazapril-treated group showed the opposite result: there was a significant regression in five, and aggravation in none of the patients. In the group
Results
receiving combined treatment, regression occurred Comparability of study groups in three, aggravation in one, and changes of р50 g in two patients.
2
-analysis revealed a significant There were no significant differences in baseline (P Ͻ 0.05) correlation between the proportion of clinical characteristics between the treatment these categorical variables (regression, aggravation groups as regards gender, age, weight or BP or insignificant change) and the kind of treatment. (Table 1 ). The baseline LVMI in the group of patients
The RWT values exhibited only minor variations, treated with the minoxidil-based regimen seemed to but with the value of 0.45 for RWT as a cut-off cribe somewhat lower than in the other groups, but this terion, the changes in mean RWT indicate a tenddifference was not statistically significant either in ency to shift from eccentric towards concentric LVH comparison with the other two groups (by ANOVA in both the minoxidil-and the cilazapril-treated on ranks; Table 1 ) or in comparison with the cilazapgroups. ril-treated group (by the Student's t-test).
Correlation between BP and LVMI BP response
In each group there was a significant decrease in BP At baseline, LVMI correlated significantly with DBP (r = 0.440, P = 0.028) and MAP (r = 0.410, P = 0.040), due to the treatment, and a satisfactory BP control Values are means ± s.d. *P Ͻ 0.05 vs the entry value, by Student's t-test for paired data. SBP = systolic blood pressure; DBP = diastolic blood pressure; MAP = mean arterial pressure; HR = heart rate; LVIDd = left ventricular internal diastolic diameter; IVST = interventricular septum thickness; PWT = posterior wall thickness; RWT = relative wall thickness; LVM = left ventricular mass; LVMI = left ventricular mass index; EF = ejection fraction; TPR = total peripheral resistance.
but not with SBP (r = 0.047, P = 0.816), as calculated Clinical symptoms and metabolic effects for the data on all the 26 patients by Spearman rank correlation analysis. Such correlations between BP There were no major cardiovascular events (myocardial infarction, pulmonary edema, stroke, and LVMI were found neither during the 'run-in' period (under the bopindolol+guanfacine therapy) etc) or death in any cases. Chest pain occurred at rest or during exercise, but dyspnea only during nor during the 12-month study period. The univariate analysis of the changes in LVMI in relation to exercise. At the beginning of the study, ankle edema occurred only in the evening, but in some patients the changes in BP parameters after 12 months of treatment revealed no statistically significant correit also appeared in the daytime during the treatment with minoxidil. In three of the minoxidil-treated lations. Stepwise multiple regression analysis with changes in LVMI as dependent, and the mode of patients, the dose of diuretics had to be increased during the study in order to control volume retentherapy and changes in MAP, SBP or DBP as independent variables, showed that the kind of therapy tion. In the minoxidil group, the incidence of ankle edema was greater (6/6) among those taking a dose was the only significant explanatory variable with an F value of 5.13 (P Ͻ 0.05) for the change in LVMI.
of minoxidil greater than 20 mg/day than in patients Values are means ± s.e.m. *P Ͻ 0.05 vs the entry ('0'-month) value (ANOVA for repeated measures, followed by the Bonferroni t-test or Friedman's repeated measures ANOVA on ranks, followed by Dunn's test). 
cated an aggravating effect of the chronic administration of minoxidil on LVH; however, the evalu- treated 23 hypertensive patients with a minoxidil+furosemide+␤-blocker combination for 24 months and found highly significant increases in taking less than 20 mg daily (1/4; P Ͻ 0.05 by the LVM. On the other hand, Julien et al 21 administered Fisher exact test). In the minoxidil+cilazapril group, a similar minoxidil-based therapy to 14 patients for only three of the patients required diuretic. The a 6-month period, but observed only insignificant McNemar test indicated that there were no significhanges in LVMI, and concluded that the minoxidilcant differences between the three groups in the based therapy failed to reduce LVH. In our study, incidence of clinical symptoms (chest pain, dyspnea LVMI increased continuously during the minoxidilor nycturia) during the treatment, but the symptoms based therapy, a statistically significant difference in tended to worsen in the minoxidil-treated group, LVMI being attained by the end of the 9th month. and to diminish in the cilazapril-treated group. No
In fact, as calculated from their data, Julien et al 21 significant metabolic side effects such as changes in observed a similar monthly rate of increase in LVMI serum lipids, glucose, blood urea nitrogen, or creati-(about 1.5 g/m 2 ), but this had not reached statistical nine were noted. Minoxidil did not cause hypertrisignificance by the end of their 6-month study. As chosis with a severity which would have necessipointed out by Devereux and Dahlö f, 30 the length of tated the cessation of treatment, either in men or the treatment period for the determination of agentin women.
dependent changes in LVMI should be at least 1 year. Accordingly, we consider that the results of
Dicussion
Julien et al 21 may also indicate an LVH-aggravating effect of minoxidil. The main findings of this study on hypertensive Additionally, we found a significant positive corpatients with LVH are that the minoxidil-based therrelation between the daily dose of minoxidil and the apy led to an increase, and the cilazapril-based regichange in LVMI in the minoxidil-treated group, men to a decrease in LVM, while treatment with a which suggests a dose-dependent LVH-aggravating combination of these drugs did not change LVM, in effect of minoxidil. A similar dose-dependence was spite of a comparable BP reduction being achieved observed as concerns the development of ankle in each group.
This study confirms the result of the only earlier edema. Earlier studies reported the occurrence of ankle edema during minoxidil treatment, even in pared to the entry status, the minoxidil-based therapy led to a more severe concentric LVH. On the combination with diuretics. [18] [19] [20] [21] A worsening of edema formation has also been observed in patients other hand, the cilazapril-based regimen resulted in a less severe concentric LVH, with a shift towards with chronic heart failure during long term minoxidil treatment, in spite of advantageous changes in concentric remodelling. Previously published data 4, 5 suggest that these changes in cardiac mass some hemodynamic parameters (increased cardiac index and decreased systemic vascular resistance) and anatomy may predict a possibly improved prognosis in the cilazapril-treated group, in contrast with being achieved by acute application of the drug.
31-33
Only a few human studies have been performed a possibly worse prognosis for the minoxidiltreated group. in which the effects of cilazapril treatment on LVH were examined in hypertensives. Only three of the Minoxidil, however, may be useful for the treatment of patients with resistant hypertension and human studies lasted for 12 months; in one of them, 34 nine patients with severe hypertension who renal involvement, eg, nephrosclerosis, 16, 17 who often have LVH and in whom ACE inhibitor treatwere on cilazapril therapy displayed an average 43 g decrease in LVM, which is comparable with the 48 g ment alone could worsen the renal function. 48 We therefore combined minoxidil with cilazapril in decrease in LVM observed in the present study. The other long-term studies 35,36 also demonstrated the order to examine whether this ACE inhibitor could prevent the LVM-increasing effect of minoxidil. To potency of this drug in reversing LVH.
Elevated arterial BP is usually considered to be a our knowledge, this is the first study which demonstrates that administration of a long-acting, potent principal stimulus for hypertensive cardiac hypertrophy, but in fact only relatively weak corre-ACE-inhibitor may overcome this adverse effect of minoxidil in human hypertensives. lations were found to exist between clinical BPs and LVM in previous studies, [37] [38] [39] [40] [41] [42] as in the present one.
In animal experiments, chronic administration of minoxidil leads to an eccentric LVH, while in comThere are a number of haemodynamic and nonhaemodynamic factors which also influence the bination with a diuretic it results in concentric LVH, 13, 41, 49 as in the present study. Also during ciladevelopment of LVH, such as the elevated wall stress caused by a pressure or volume overload, genzapril treatment, the left ventricular anatomy showed a change from eccentric to concentric LVH, der, race, obesity, alcohol and sodium intake, blood viscosity, catecholamines, angiotensin II, or growth although no diuretics were used in this group. It could be suggested that the inhibition of the reninhormone. 2, 43 As concerns the effect of BP reduction by different types of therapy on changes in LVM, angiotensin-aldosterone system by cilazapril may contribute to the regression of volume overloadstepwise regression analysis showed that the type of therapy and not changes in arterial pressures coninduced LVH by decreasing the intravascular volume. Furthermore, angiotensin II generated in the tributed significantly to explaining the change in cardiac mass, as in a previous study comparing the heart seems to be an important mediator of the hypertrophic response to a cardiac overload, and effects of enalapril and hydrochlorothiazide on LVM. 44 thus, the ability of ACE inhibitors to reverse LVH may also be related to their inhibitory effect on carThe simplification that LVH in essential hypertension is a consequence of an elevated BP and diac tissue ACE.
50,51
We are aware of the limitations of this study. increased afterload may lead to the suggestion that reduction of the afterload with a direct vasodilator Nevertheless, these results, taken together with those reported by others, 20,34-36 empower us to draw drug, eg, minoxidil, could reverse LVH. In contrast with this, as demonstrated by numerous expericonclusions as follows. The ACE inhibitor cilazapril is effective in reversing LVH in hypertensive mental studies, the chronic administration of minoxidil, by leading to stimulation of the sympathpatients. Minoxidil should be reserved for the treatment of patients with severe, therapy-resistant etic and renin-angiotensin systems and volume overload, is able to induce LVH in normotensive hypertension and should not be employed in patients with overt cardiac hypertrophy or weakanimals or to aggravate pre-existing LVH, with no improvement in survival. [12] [13] [14] [15] Our results showing a ness. In order to prevent the LVH-and volume overload-inducing effects of minoxidil, it should be decrease in TPR with increasing tendencies in cardiac output and edema formation are also suggestive applied in the smallest effective dose (15-20 mg daily) and combined not only with the usually of the development of a volume overload during minoxidil treatment. Other vasodilator drugs such administered diuretics and ␤-blockers, but also with an effective ACE inhibitor with properties like those as hydralazine and prazosine, which are less effective in decreasing TPR and in increasing renin of cilazapril, under careful control, including an echocardiographic follow-up. release and the intravascular volume, do not aggravate LVM to such an extent as minoxidil. 28, 45, 46 
